Promore Pharma modifies its Phase III trial of PXL01 and expands the number of clinics in the study
STOCKHOLM, February 1, 2019 - Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that the company is making adjustments to the manufacturing chain of the investigational medicinal product for the company's clinical phase III study, PSHU03, with PXL01 for prevention of adhesions following tendon repair surgery. The adjustments mean that the provision of investigational medicinal product is delayed. To minimize the overall delay, the company intends to increase the number of clinics in order to enable faster recruitment of patients to the study.